Showing results (311-320 of 335) with videos related to
Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsGayle S Jameson, John T Hamm, Glen J Weiss, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.Molecular Cancer Therapeutics|October 22, 2017
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid TumorsElaine T Lam, S Gail Eckhardt, Wells Messersmith, et al.Cancer Chemotherapy and Pharmacology|April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyTiciana B Leal, Scot C Remick, Chris H Takimoto, et al.Journal of the American College of Cardiology|July 14, 2001
Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME)D A Morrison, G Sethi, J Sacks, et al.Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasA Patnaik, L J Appleman, A W Tolcher, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancerColin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.Plos One|February 4, 2014
Integrated genomic and epigenomic analysis of breast cancer brain metastasisBodour Salhia, Jeff Kiefer, Julianna T D Ross, et al.Pageof 34